Missing Novelty in Drug Development
收藏NBER2018-05-01 更新2025-01-04 收录
下载链接：
https://www.nber.org/papers/w24595
下载链接
链接失效反馈官方服务：
资源简介：
This paper provides evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We define a drug candidate as novel if it is molecularly distinct from prior candidates. Using our measure, we show that firms face a risk-reward tradeoff when investing in novel drugs:
提供机构：
美国国家经济研究局
创建时间：
2018-05-01
